Monday, November 3, 2025 11/3/2025

Harnessing endothelial cell transdifferentiation for cardiovascular therapy

Award Number: R15HL165397
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

Harnessing endothelial cell transdifferentiation for cardiovascular therapy - Cardiovascular disease is the leading cause of death, so recent efforts have focused on using emerging genetic technologies to remediate cardiac and vascular pathologies. These efforts are largely based on a growing number of studies, including our preliminary data, that have observed transgene delivery to cardiac myocytes via intravenous injection of a viral vector. However, to date, there is no empirically backed rationale for any mechanism underlying this important finding. My lab has focused on the prospect of endothelial cell transdifferentiation for many years and accrued evidence that this process exists in adult mice and may be responsible for the homeostasis of diverse cell types. Our preliminary data coupled with our proposed approach will determine whether cardiac myocyte labeling is the result of a transdifferentiation event (endothelial cell or otherwise) or the product of extracellular vesicle transfer. This work will also confirm whether the source of this labeling is endothelial cells. We are also interested in determining the nature of intravenous transgene delivery to other cell types, which could yield information about the localization of endothelial cell transdifferentiation to discrete niches. The existence of such niches could have important implications for enhancing the vascular pathology of those regions. This work will be undertaken using separate state-of-the-art cell lineage tracing strategies that encompass virus, protein, and cell-based methods. The answers provided by this study will help guide efforts for cardiac genetic therapy, advance our understanding of endothelial cell biology, and provide potentially new insights into cardiovascular disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	BOISE STATE UNIVERSITY	1910 UNIVERSITY DR	BOISE	ID	83725	ADA	USA	Cardiovascular Diseases Research	000	1	7/24/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $408,731 )
2022	2022	BOISE STATE UNIVERSITY	1910 UNIVERSITY DR	BOISE	ID	83725	ADA	USA	Cardiovascular Diseases Research	000	1	8/11/2022	NEW	$408,731
														Subtotal = $408,731

Grand Total All Awards = $408,731

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Harnessing endothelial cell transdifferentiation for cardiovascular therapy

Award Number: R15HL165397

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer